Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>In the evolving landscape of isotope production, ASP Isotopes stands poised for significant growth.</li><li>With production scalability and a substantial interest backlog, ASP Isotopes is on the cusp of substantial free cash flow realization in 2024.</li><li>Currently undervalued, the stock presents a rare opportunity for early investors to capitalize on ASP Isotopes' anticipated market ascendancy and potential to redefine secure isotope supply chains globally.</li></ul>

In the evolving landscape of isotope production, ASP Isotopes stands poised for significant growth.With production scalability and a substantial interest backlog, ASP Isotopes is on the cusp of substantial free cash flow realization in 2024.Currently undervalued, the stock presents a rare opportunity for early investors to capitalize on ASP Isotopes' anticipated market ascendancy and potential to redefine secure isotope supply chains globally.

<ul>
<li>This is our first report on ASP Isotopes and we look to provide a detailed account of the various assets owned by the company and the drivers that will be responsible for the company’s growth in the coming years.</li>
<li>ASP Isotopes’ proprietary isotope enrichment technology should enable the company to produce many of these isotopes, as shown in the diagram below.</li>
<li>When combined with the company’s second manufacturing plant, scheduled to start production during 2H 2023, ASP Isotopes should generate substantial free cash flow during 2024.</li>
</ul>


This is our first report on ASP Isotopes and we look to provide a detailed account of the various assets owned by the company and the drivers that will be responsible for the company’s growth in the coming years.
ASP Isotopes’ proprietary isotope enrichment technology should enable the company to produce many of these isotopes, as shown in the diagram below.
When combined with the company’s second manufacturing plant, scheduled to start production during 2H 2023, ASP Isotopes should generate substantial free cash flow during 2024.


ASP Isotopes - Initiation of Coverage Report - Isotope Market Overview

United States

ASP Isotopes Inc. operates a pre-commercial stage advanced materials company. The Company focuses on production of high value and low volume isotopes for medical, nuclear power, and other industries. ASP Isotopes serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ASP Isotopes (ASPI US)

ASP Isotopes: New Alliance With PET Labs

In the evolving landscape of isotope production, ASP Isotopes stands poised for significant growth. With production scalability and a substantial...

Baptista Research

ASP Isotopes - Initiation of Coverage Report - Isotope Market Overview

This is our first report on ASP Isotopes and we look to provide a detailed account of the various assets owned by the company and the drivers that...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)